VOOZH about

URL: https://www.nature.com/subjects/pharmacogenomics?error=cookies_not_supported&code=0d3e02fc-3753-4575-8d5a-0fcfa62dbcda

⇱ Pharmacogenomics - Latest research and news | Nature


Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pharmacogenomics articles from across Nature Portfolio

Pharmacogenomics is the study of how genetic variation influences responses to drugs. This includes how genetic variants affect drug metabolism, efficacy and toxicity, with the goal of improving and personalizing drug therapy.

Latest Research and Reviews

All Research & Reviews

News and Comment

  • In this era of rapidly expanding human genomics in research and healthcare, efficient data reuse is essential to maximize benefits for society. In response, the Federated European Genome–Phenome Archive (FEGA) was launched in 2022, and as of 2024, the FEGA network was composed of seven national nodes. Here we describe the complexities, challenges and achievements of FEGA, unravelling the dynamic interplay of regulatory frameworks, technical challenges and the shared vision of advancing genomic research.

    • Teresa D’Altri
    • Mallory Ann Freeberg
    • Thomas M. Keane
    Comments & Opinion Nature Genetics
    Volume: 57, P: 481-485
  • Innovative pharmacogenomic approaches (genetic variation related to medication response) are needed to reduce disease and disparities in Indigenous communities. We support community-based pharmacogenomics research, inclusive of Indigenous values and priorities, to improve the health and well-being of Indigenous peoples.

    • Katrina G. Claw
    • Casey R. Dorr
    • Erica L. Woodahl
    Comments & OpinionOpen Access Nature Communications
    Volume: 15, P: 920
  • Indigenous peoples are under-represented in genomic datasets, which can lead to limited accuracy and utility of machine learning models in precision health. While open data sharing undermines rights of Indigenous communities to govern data decisions, federated learning may facilitate secure and community-consented data sharing.

    • Nima Boscarino
    • Reed A. Cartwright
    • Krystal S. Tsosie
    Comments & Opinion Nature Machine Intelligence
    Volume: 4, P: 909-911
  • The Pharmacogenomics Access & Reimbursement Symposium, a landmark event presented by the Golden Helix Foundation and the Pharmacogenomics Access & Reimbursement Coalition (PARC), was a one-day interactive meeting comprised of plenary keynotes from thought leaders across health care that focused on value-based strategies to improve patient access to personalized medicine. Stakeholders including patients, healthcare providers, industry, government agencies, payer organizations, health systems and health policy organizations convened to define opportunities to improve patient access to personalized medicine through best practices, successful reimbursement models, high-quality economic evaluations, and strategic alignment. Session topics included health technology assessment, health economics, health policy, and value-based payment models and innovation.

    • Sara L. Rogers
    • George P. Patrinos
    • Benjamin G. Brown
    News & Views The Pharmacogenomics Journal
    Volume: 21, P: 622-624
All News & Comment

Search

Advanced search

Quick links